スポンサーサイト

上記の広告は1ヶ月以上更新のないブログに表示されています。
新しい記事を書く事で広告が消せます。


Cancer Topics Index 04/18/2016(Daily Test version/ 日刊テスト版)No.12

konpas.jpg
Cancer Topics Index 04/18/2016(Daily Test version/ 日刊テスト版) No.12

Flags 【海外:overseas】
◇NIH (National Institutes of Health)◇
【家の周囲の緑とがん死亡率】
10280-01.jpg
Greenness around homes linked to lower mortality (April 15, 2016 News Release:NIH)
Women live longer in areas with more green vegetation, according to new research funded by the National Institute of Environmental Health Sciences (NIEHS), part of the National Institutes of Health. Women with the highest levels of vegetation, or greenness, near their homes had a 12 percent lower death rate compared to women with the lowest levels of vegetation near their homes. The results were published April 14 in the journal Environmental Health Perspectives.

logo-clinicaltrials-gov.png
rinnsyo1.jpg

※2週間前の情報を基準として掲載。一部の記事(がんと直接関連しないもの)は割愛しています。
17 studies found for: cancer | received from 04/02/2016 to 04/04/2016

【乳がん】
1 Recruiting
PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
Condition: Breast Cancer
Interventions: Other: Plasma/Buffy Coat; Other: Serum; Other: Bone Marrow Aspirate
Sponsor:Abramson Cancer Center of the University of Pennsylvania
ClinicalTrials.gov Identifier:NCT02732171

【膵がん】
2 Not yet recruiting
Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery
Condition: Pancreatic Adenocarcinoma
Interventions: Drug: Cetuximab-IRDye 800CW; Procedure: Intraoperative Imaging; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; Procedure: Photoacoustic Imaging; Procedure: Therapeutic Conventional Surgery
Sponsor:Eben Rosenthal
ClinicalTrials.gov Identifier:NCT02736578

【胃がん】
3 Recruiting
Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.
Condition: Gastric Cancer
Interventions: Drug: S-1 for 6 months; Drug: S-1 for 1 year
Sponsor:Sun Yat-sen University
ClinicalTrials.gov Identifier:NCT02736552

【非小細胞肺がん】
4 Recruiting
RT Plus EGFR-TKI for Wild-type NSCLC
Conditions: Non-small Cell Lung Cancer; Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)
Interventions: Drug: Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®); Radiation: Radiotherapy
Sponsor:Hangzhou Cancer Hospital
ClinicalTrials.gov Identifier:NCT02738983

【乳がん】
5 Not yet recruiting
Study of Ribociclib With Everolimus + Exemestane in HR+ HER2- Locally Advanced/Metastatic Breast Cancer Post Progression on CDK 4/6 Inhibitor.
Condition: Breast Cancer
Interventions: Drug: Ribociclib; Drug: Everolimus; Drug: Exemestane
Sponsor:Novartis Pharmaceuticals
ClinicalTrials.gov Identifier:NCT02732119

【乳がん】
6 Recruiting
Physiotherapy in Chronic Shoulder Pain After Breast Cancer Treatment
Conditions: Shoulder Pain; Breast Cancer
Interventions: Other: Shoulder Conventional Exercises; Other: Invasive PT; Device: Control Motor Exercises; Behavioral: Therapeutic Education
Sponsor:University of Alcala
ClinicalTrials.gov Identifier:NCT02735668

【腹膜がん】
7 Active, not recruiting
Role of Intraperitoneal Intraoperative Chemotherapy With Paclitaxel in the Surgical Treatment of Peritoneal Carcinomatosis From Ovarian Cancer. Hyperthermia Versus Normothermia
Condition: Peritoneal Carcinomatosis
Interventions: Drug: Paclitaxel; Procedure: Radical surgery-peritonectomy
Sponsor:Maimónides Biomedical Research Institute of Córdoba
ClinicalTrials.gov Identifier:NCT02739698

【消化器がん】
8 Enrolling by invitation
COMplementary Hand-foot Massage to Improve Experience of illneSs Trial
Condition: Gastrointestinal Cancer
Interventions: Other: Usual post-operative care; Other: Usual post-operative care in combination with hand-foot massage
Sponsor:Zuyderland Medisch Centrum
ClinicalTrials.gov Identifier:NCT02741401

【悪性腫瘍】
9 Not yet recruiting
Dose Evaluation of MK-1966 in Combination With SD-101 in Participants With Advanced Malignancies (MK-1966-001)
Condition: Neoplasms, Advanced
Interventions: Biological: MK-1966; Drug: SD-101
Sponsor:Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:NCT02731742

【非小細胞肺がん】
10 Recruiting
Study Comparing 2 Strategies in Patients With SCLC on the 2nd Row With Relapsed After Response to Chemotherapy
Condition: Small Cell Lung Cancer
Interventions: Drug: Carboplatin; Drug: Etoposide; Drug: Topotecan; Device: CT scans
Sponsor:University Hospital, Angers
ClinicalTrials.gov Identifier:NCT02738346

【非ホジキンリンパ腫】
11 Recruiting
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Condition: Non-Hodgkin Lymphoma
Intervention:
Sponsor:Mayo Clinic
ClinicalTrials.gov Identifier:NCT02736357

【リンパ腫】
12 Recruiting
A Phase 1 Multiple Ascending Dose Study of DS-3201b in Japanese Subjects With Lymphomas
Conditions: Lymphoma; Lymphoma, B-cell; Lymphoma, Follicular; Adult T-Cell Leukemia Lymphoma (ATLL)
Intervention: Drug: DS-3201b
Sponsor:Daiichi Sankyo Co., Ltd.
ClinicalTrials.gov Identifier:NCT02732275

【黒色腫】
13 Recruiting
Ipilimumab vs Ipilimumab Plus Nivolumab in Patients With Stage III-IV Melanoma Who Have Progressed or Relapsed on PD-1 Inhibitor Therapy
Condition: Melanoma
Interventions: Drug: ipilimumab; Drug: nivolumab
Sponsor:Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov Identifier:NCT02731729

【肉腫】
14 Not yet recruiting
Effects of Rolapitant on Nausea/Vomiting in Patients With Sarcoma Receiving Multi-Day Highly Emetogenic Chemotherapy (HEC) With Doxorubicin and Ifosfamide Regimen (AI)
Condition: Sarcoma
Interventions: Drug: Rolapitant; Drug: Fosaprepitant; Behavioral: Questionnaires; Drug: Dexamethasone; Drug: Ondansetron; Drug: Doxorubicin; Drug: Mesna; Drug: Ifosfamide; Drug: Vincristine
Sponsor:M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:NCT02732015

【ユーイング肉腫】
15 Not yet recruiting
Pbi-shRNA™ EWS/FLI1 Type 1 LPX in Subjects With Advanced Ewing's Sarcoma
Condition: Ewing's Sarcoma
Intervention: Biological: pbi-shRNA™ EWS/FLI1 Type 1 LPX
Sponsor:Strike Bio, Inc.
ClinicalTrials.gov Identifier:NCT02736565

【リンパ腫】
16 Recruiting
Marginal Zone Lymphoma Cohort in Korea
Condition: Lymphoma, B-Cell, Marginal Zone
Intervention: Other: Rituximab
Sponsor:Dong-A University Hospital
ClinicalTrials.gov Identifier:NCT02732236

【急性骨髄性白血病/骨髄異形成症候群】
17 Not yet recruiting
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
Conditions: Acute Myeloid Leukemia; Myelodysplastic Syndrome
Intervention: Drug: Co-ArgI-PEG modified human arginase I
Sponsor:Aeglea Biotherapeutics
ClinicalTrials.gov Identifier:NCT02732184

<Pharmaceuticals and Medical Devices>
【非小細胞肺がん】
Head-to-head study demonstrating Giotrif® (afatinib) significantly improved clinical outcomes compared to Iressa® (gefitinib) in EGFR mutation-positive advanced non-small cell lung cancer published in The Lancet Oncology (13 April 2016 boehringer-ingelheim)
治療歴のないEGFR遺伝子変異陽性非小細胞肺がん(NSCLC)患者を対象に、第二世代のEGFR阻害薬アファチニブと第一世代のEGFR阻害薬を直接比較した試験の結果がランセットオンコロジーに発表 (04/14/2016 ベーリンガーインゲルハイム Boehringer Ingelheim)
アファチニブ(製品名:ジオトリフ®)は、EGFR遺伝子変異陽性NSCLC患者の一次治療薬として、60ヵ国以上で承認を取得しています。日本ではEGFR遺伝子変異陽性の手術不能又は再発非小細胞肺癌の効能・効果で承認を取得しています。この適応症でアファチニブが承認される根拠となったのは、LUX-Lung 3試験の主要評価項目であるPFSであり、アファチニブは標準的な化学療法と比べて腫瘍増殖を有意に遅延させました3。さらに、アファチニブは、特定のEGFR遺伝子変異を有するNSCLC患者において化学療法と比較して全生存期間のベネフィットを示した最初の治療薬であり4、LUX-Lung 3およびLUX-Lung 6のそれぞれにおいて、発現頻度の高いEGFR遺伝子変異(del19)を有する患者に対し化学療法と比較したアファチニブによる全生存期間のベネフィットが示されました。

<Medical Journal & Other News>
headline.jpg
【LOXO-101の様々ながんにおける腫瘍退縮】American Association for Cancer Research Annual Meeting 2016
Study drug LOXO-101 shows tumor regression in varied cancers (04/17/2016 EurekAlert!/UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER)
A phase I study of the drug LOXO-101 appears to significantly reduce tumors in patients with varied types of genetically defined cancer, according to a study led by The University of Texas MD Anderson Cancer Center.The results of the study, which followed patients with unique proteins called tropomyosin receptor kinase fusions (TRKs), were presented at the American Association for Cancer Research's annual meeting held April 16-20 in New Orleans.

【膵がん治療のためのEngineering T細胞】American Association for Cancer Research 2016 Annual Meeting
Engineering T cells to treat pancreatic cancer (04/16/2016 EurekAlert!/FRED HUTCHINSON CANCER RESEARCH CENTER)
SEATTLE AND NEW ORLEANS - Dr. Sunil Hingorani, a member of the Clinical Research and Public Health Sciences divisions at Fred Hutchinson Cancer Research Center, will present recent groundbreaking developments in treating pancreas cancer with engineered T-cells at the American Association for Cancer Research Annual Meeting 2016 in New Orleans on April 16.

【甲状腺がん】JOURNAL:JAMA Oncology
Nomenclature Revision for Encapsulated Follicular Variant of Papillary Thyroid Carcinoma (April 14, 2016)
米癌学会、甲状腺癌の一部を癌の分類から除外・癌治療は不要に (04/15/2016 businessnewsline)
※これまで甲状腺癌と見なされてきた「encapsulated thyroid tumors(癌腫の一種)」を癌の分類から除外したことを発表

Graphics 【日本国内:Japan】
<Press Release:日本国内>
【地震での被災】
0419.jpg
熊本県熊本地方を震源とする地震で被災なさった方へ 熊本県・大分県のがん相談支援センターの相談対応状況について (04/18/2016 国立がん研究センター)
熊本県のがん相談支援センター
大分県のがん相談支援センター

【膵臓がん】
膵臓がん患者に有効な治療臨床試験が始まっています 本学外科学講座・里井壯平准教授らの研究チームが、世界で初めて有効性を確認 (04/05/2016 関西医科大学) pdf
Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. (PubMed/Ann Surg. 2016 Mar 11)

<厚生労働省(MHLW)/文部科学省(MEXT)・その他省庁>
【臨床試験】
第2回 臨床開発環境整備推進会議 資料 (04/15/2016 厚生労働省:MHLW)
臨床試験課題レジストリの構築状況 今後の方向性 (国立がん研究センター) pdf

<News>
【医療コスト】
医療とコスト 高額の薬が問う「命の値段」(04/16/2016 朝日新聞デジタル)

【新規治療標的】
がん研、染色体不安定性を利用した新規な治療標的を提案 Survey(2016年3月20日号)(04/15/2016 日経メディカル癌Expert)

【小児ホスピス】
難病とともに暮らす子どもの成長に“友人のような立ち位置”から寄り添う~日本初の「コミュニティ型子ども向けホスピス」が誕生 (04/15/2016 BLOGAS)

【がんになる確率】
数字に惑わされてはダメ!国民病と呼ばれるがんの「本当の確率」(04/14/2016 woman.excite)

<新刊メタデータ:New Books>
book_sepia.jpg
【タイトル】あなたはそこにいるだけで価値ある存在
著者:樋野 興夫/単行本: 207ページ/出版社: KADOKAWA (2016/4/15)/ISBN-10: 4046015543/ISBN-13: 978-4046015549/¥1,188
関連記事


コメント
コメントの投稿


管理者にだけ表示を許可する

トラックバック
http://paxxmedia.blog38.fc2.com/tb.php/9058-76a8837a
この記事にトラックバックする(FC2ブログユーザー)


上記広告は1ヶ月以上更新のないブログに表示されています。新しい記事を書くことで広告を消せます。